NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP announces that it has commenced an investigation of Chimerix, Inc. (“Chimerix” or “the Company”) (NasdaqGM:CMRX) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
On December 28, 2015, the Company reported the failure in a Phase 3 study of their lead product candidate, Brincidofovir. Upon this news, shares of Chimerix have lost over 80% of their value in intraday trading, dropping below $7.00 per share from a closing price of $35.57 on December 24, 2015. To obtain additional information about the investigation, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.